TWD 21.95
(-3.73%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | 194.21 Million TWD | -8.35% |
2022 | 211.9 Million TWD | 45.7% |
2021 | 145.43 Million TWD | 10.17% |
2020 | 132 Million TWD | -13.22% |
2019 | 152.12 Million TWD | 11.16% |
2018 | 136.84 Million TWD | -9.72% |
2017 | 151.57 Million TWD | -4.85% |
2016 | 159.29 Million TWD | -24.05% |
2015 | 209.75 Million TWD | -6.69% |
2014 | 224.79 Million TWD | 23.27% |
2013 | 182.36 Million TWD | -23.82% |
2012 | 239.37 Million TWD | 11.11% |
2011 | 215.44 Million TWD | -4.05% |
2010 | 224.54 Million TWD | -7.1% |
2009 | 241.7 Million TWD | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q1 | 48.71 Million TWD | -0.06% |
2024 Q2 | 28.76 Million TWD | -40.95% |
2023 Q3 | 40.56 Million TWD | -48.44% |
2023 Q4 | 48.74 Million TWD | 20.17% |
2023 FY | 194.21 Million TWD | -8.35% |
2023 Q1 | 67.19 Million TWD | 198.77% |
2023 Q2 | 78.66 Million TWD | 17.06% |
2022 Q2 | 69.72 Million TWD | 64.21% |
2022 Q4 | 22.49 Million TWD | -70.88% |
2022 FY | 211.9 Million TWD | 45.7% |
2022 Q3 | 77.22 Million TWD | 10.75% |
2022 Q1 | 42.46 Million TWD | 283.82% |
2021 Q3 | 33.9 Million TWD | 21.59% |
2021 Q4 | 11.06 Million TWD | -67.37% |
2021 Q1 | 46.37 Million TWD | 4323.86% |
2021 Q2 | 27.88 Million TWD | -39.87% |
2021 FY | 145.43 Million TWD | 10.17% |
2020 Q2 | 60.99 Million TWD | 601.43% |
2020 Q1 | 8.69 Million TWD | -77.9% |
2020 FY | 132 Million TWD | -13.22% |
2020 Q4 | -1.09 Million TWD | -103.89% |
2020 Q3 | 28.22 Million TWD | -53.73% |
2019 Q3 | 21.47 Million TWD | -25.84% |
2019 FY | 152.12 Million TWD | 11.16% |
2019 Q1 | 43.31 Million TWD | -9.19% |
2019 Q2 | 28.95 Million TWD | -33.16% |
2019 Q4 | 39.34 Million TWD | 83.22% |
2018 Q1 | 32.73 Million TWD | 356.49% |
2018 FY | 136.84 Million TWD | -9.72% |
2018 Q4 | 47.69 Million TWD | 82.05% |
2018 Q3 | 26.2 Million TWD | -13.29% |
2018 Q2 | 30.21 Million TWD | -7.68% |
2017 Q4 | 7.17 Million TWD | -81.74% |
2017 Q1 | 40.48 Million TWD | 41.37% |
2017 Q3 | 39.25 Million TWD | -39.29% |
2017 Q2 | 64.66 Million TWD | 59.73% |
2017 FY | 151.57 Million TWD | -4.85% |
2016 FY | 159.29 Million TWD | -24.05% |
2016 Q1 | 55.5 Million TWD | 8.84% |
2016 Q2 | 50.25 Million TWD | -9.46% |
2016 Q3 | 24.89 Million TWD | -50.46% |
2016 Q4 | 28.63 Million TWD | 15.02% |
2015 Q4 | 50.99 Million TWD | 383.71% |
2015 Q3 | 10.54 Million TWD | -86.07% |
2015 Q2 | 75.7 Million TWD | 4.4% |
2015 Q1 | 72.51 Million TWD | 927.94% |
2015 FY | 209.75 Million TWD | -6.69% |
2014 Q4 | 7.05 Million TWD | -89.26% |
2014 Q3 | 65.65 Million TWD | -21.1% |
2014 Q1 | 68.87 Million TWD | 60.24% |
2014 FY | 224.79 Million TWD | 23.27% |
2014 Q2 | 83.2 Million TWD | 20.81% |
2013 Q4 | 42.98 Million TWD | 83.84% |
2013 FY | 182.36 Million TWD | -23.82% |
2013 Q3 | 23.38 Million TWD | -63.47% |
2013 Q2 | 64 Million TWD | 23.1% |
2013 Q1 | 51.99 Million TWD | 23.65% |
2012 Q1 | 62.91 Million TWD | 9.42% |
2012 FY | 239.37 Million TWD | 11.11% |
2012 Q3 | 47.32 Million TWD | -39.03% |
2012 Q2 | 77.62 Million TWD | 23.4% |
2012 Q4 | 42.05 Million TWD | -11.15% |
2011 Q1 | 72.96 Million TWD | 138.46% |
2011 FY | 215.44 Million TWD | -4.05% |
2011 Q2 | 43.28 Million TWD | -40.68% |
2011 Q3 | 41.71 Million TWD | -3.63% |
2011 Q4 | 57.49 Million TWD | 37.84% |
2010 Q3 | 37.95 Million TWD | -55.67% |
2010 FY | 224.54 Million TWD | -7.1% |
2010 Q4 | 30.59 Million TWD | -19.38% |
2010 Q1 | 70.37 Million TWD | 0.0% |
2010 Q2 | 85.61 Million TWD | 21.65% |
2009 FY | 241.7 Million TWD | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
Excelsior Medical Co., Ltd. | 702.88 Million TWD | 72.368% |
OK Biotech Co., Ltd. | -12.06 Million TWD | 1710.172% |
Applied BioCode Corporation | -186.7 Million TWD | 204.026% |